Small Pilot Study Evaluates Etokimab as a Potential Treatment for Peanut Allergy

Understanding Peanut Allergy

A peanut allergy can trigger severe symptoms, including hives, oral and throat itching, respiratory issues like wheezing, and in extreme cases, anaphylactic shock. Symptoms of anaphylactic shock include airway constriction, low blood pressure, throat swelling, and potential loss of consciousness.

Study Overview and Objective

A research team published findings in JCI Insights on a pilot study examining the efficacy of etokimab, an anti-IL-33 monoclonal antibody, as a treatment for peanut allergy. Interleukin 33 (IL-33) is a glycoprotein involved in regulating immune responses, particularly during allergic reactions. When an allergen, such as peanut protein, is encountered, IL-33 triggers a series of immune responses, activating immunoglobulin E (IgE) antibodies. Etokimab aims to disrupt this process by blocking IL-33 from initiating the allergic reaction cascade.

Study Methodology

The pilot study involved 20 participants diagnosed with peanut allergy. Of these, 15 received an injection of etokimab, while 5 were given a placebo. After 15 days, participants were tested by consuming 275 mg of peanut protein, roughly equivalent to one peanut, to evaluate potential allergic reactions.

Results of the Study

Among those who received etokimab, 11 participants exhibited no allergic reactions to the peanut protein. In contrast, none of the placebo group were able to tolerate the peanut protein. After 45 days, the placebo group remained unable to consume peanut protein, while 57% of the etokimab group continued to show no allergic response. Additionally, participants treated with etokimab showed lower levels of peanut-specific IgE and total IgE in their blood compared to the placebo group at the 15-day mark.

Conclusion and Future Implications

The initial findings from this pilot study indicate that targeting IL-33 with monoclonal antibodies like etokimab may be a promising approach to treating peanut allergies. The treatment was generally well tolerated and effectively prevented allergic reactions in a significant number of participants. Lead author Kari Nadeau expressed optimism about the broader applications of this treatment, stating, “Although this is still in the experimental stages, we’re delivering on the hope of testing a drug that won’t be for one food allergy but for many, and for other allergic diseases, too.”

References

Chinthrajah, S., Cao, S., Liu, C., Lyu, S.C., Sindher, S.B., Long, A., Sampath, V., Petroni, D., Londei, M., Nadeau, K.C. (2019). Phase 2a Randomized, Placebo-controlled Study of Anti-IL-33 in Peanut Allergy. JCI Insights.
Eurekalert News Release – https://www.eurekalert.org/pub_releases/2019-11/sm-ais110719.php
The Mayo Clinic – https://www.mayoclinic.org/diseases-conditions/peanut-allergy/symptoms-causes/syc-20376175
Image by PublicDomainPictures from Pixabay